Back to Journals » Clinical Ophthalmology » Volume 6

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Authors Ellabban, Tsujikawa A, Ogino K, Ooto, Yamashiro K, Oishi A, Yoshimura N

Received 15 February 2012

Accepted for publication 10 March 2012

Published 30 May 2012 Volume 2012:6 Pages 837—844

DOI https://doi.org/10.2147/OPTH.S30907

Review by Single-blind

Peer reviewer comments 2


Abdallah A Ellabban, Akitaka Tsujikawa, Ken Ogino, Sotaro Ooto, Kenji Yamashiro, Akio Oishi, Nagahisa Yoshimura
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan

Purpose: To study changes in choroidal thickness with ranibizumab treatment for choroidal neovascularization (CNV).
Design: Prospective case series.
Methods: This prospective study consisted of 60 CNV-affected eyes of 60 patients treated with intravitreal injections of ranibizumab using an on-demand protocol after an initial loading phase. The eyes studied included 20 with age-related macular degeneration (AMD), 20 with polypoidal choroidal vasculopathy (PCV), and 20 with myopic CNV. In the eyes with AMD and PCV, choroidal thickness at the fovea was measured with optical coherence tomography using enhanced depth imaging. In eyes with myopic CNV, the choroidal thickness was measured using standard optical coherence tomography without the enhanced depth imaging technique.
Results: With ranibizumab treatment, central retinal thickness decreased significantly (P < 0.001) and visual acuity improved significantly (P < 0.001). However, central choroidal thickness (167.2 ± 108.3 µm) showed no significant change at 1 month after the loading phase (165.2 ± 107.8 µm, P = 0.120) or at final examination (164.8 ± 107.7 µm, P = 0.115). At baseline, central retinal thickness in eyes with AMD was significantly greater that those with PCV (P = 0.005) or high myopia (P = 0.029). However, central choroidal thickness in eyes with myopic CNV was significantly thinner than in eyes with AMD (P < 0.001) or PCV (P < 0.001). In each type of disease, there was no significant change in central choroidal thickness with ranibizumab treatment.
Conclusion: The effect of ranibizumab on the choroidal thickness is minimal, if any.

Keywords: choroidal thickness, ranibizumab, optical coherence tomography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]